Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. Show more

Location: 2929 7th Street, Berkeley, CA, 94710, United States | Website: https://cariboubio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

151.6M

52 Wk Range

$0.66 - $3.00

Previous Close

$1.74

Open

$1.71

Volume

1,157,167

Day Range

$1.62 - $1.72

Enterprise Value

-65.06M

Cash

208.5M

Avg Qtr Burn

-34.43M

Insider Ownership

9.83%

Institutional Own.

53.30%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.